SPS-4251 [PAP-1; SPS4251; 5-(4-Phenoxybutoxy)psoralen] is a novel and potent KCNA3 channel blocker (inhibitor of Kv1.3, voltage-gated K+ channel) with the potential to be used in treatment of multiple sclerosis.